Main
|
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
Register:
|
EUCTR |
Last refreshed on:
|
10 March 2014 |
Main ID: |
EUCTR2012-001711-23-DE |
Date of registration:
|
29/11/2012 |
Prospective Registration:
|
Yes |
Primary sponsor: |
|
Public title:
|
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A
|
Scientific title:
|
A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients with Severe Haemophilia A |
Date of first enrolment:
|
31/01/2013 |
Target sample size:
|
60 |
Recruitment status: |
Not Recruiting |
URL:
|
https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2012-001711-23 |
Study type:
|
Interventional clinical trial of medicinal product |
Study design:
|
Controlled: no
Randomised: no
Open: no
Single blind: no
Double blind: no
Parallel group: no
Cross over: no
Other: no
If controlled, specify comparator, Other Medicinial Product: no
Placebo: no
Other: no
|
Phase:
|
|
|
Countries of recruitment
|
Australia
|
Brazil
|
Canada
|
European Union
|
Germany
|
Greece
|
Israel
|
Italy
|
Japan
|
Korea, Republic of
|
Lithuania
|
Macedonia, the former Yugoslav Republic of
|
Malaysia
|
Portugal
|
Switzerland
|
Turkey
|
Ukraine
|
United Kingdom
|
United States
| | | | | |
Contacts
|
Name:
|
Global Clinical Registry (GCR,1452)
|
Address:
|
Vandtaarnsvej 114,VTB
DK-2860
Soeborg
Denmark |
Telephone:
|
|
Email:
|
clinicaltrials@novonordisk.com |
Affiliation:
|
Novo Nordisk A/S |
|
Name:
|
Global Clinical Registry (GCR,1452)
|
Address:
|
Vandtaarnsvej 114,VTB
DK-2860
Soeborg
Denmark |
Telephone:
|
|
Email:
|
clinicaltrials@novonordisk.com |
Affiliation:
|
Novo Nordisk A/S |
| |
Key inclusion & exclusion criteria
|
Inclusion criteria: - Male patients with severe congenital haemophilia A (FVIII activity level < 1%)
- Age below 12 years at screening (for Turkey only: Age above 3 and below 12 years at screening)
- Weight =10 kg
- Documented history of > 150 ED to FVIII products for patients aged 6-11 years and > 50 ED to FVIII products for patients aged 0-5 years (for Turkey only: Documented history of >150 ED to FVIII products for patients aged 6-11 years and > 50 ED to FVIII products for patients aged 3-5 years) Are the trial subjects under 18? yes Number of subjects for this age range: 60 F.1.2 Adults (18-64 years) no F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range
Exclusion criteria: Any history of FVIII inhibitors
Age minimum:
Age maximum:
Gender:
Female: no Male: yes
|
Health Condition(s) or Problem(s) studied
|
Haemophilia A MedDRA version: 14.1
Level: LLT
Classification code 10018938
Term: Haemophilia A (Factor VIII)
System Organ Class: 100000004850
|
Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16]
|
Intervention(s)
|
Product Name: N8-GP rFVIII Pharmaceutical Form: Powder and solvent for solution for injection INN or Proposed INN: N/A CAS Number: 1309086-46-1 Current Sponsor code: NNC129-1003 Concentration unit: U unit(s) Concentration type: equal Concentration number: 2000-
Product Name: N8-GP 500U vial Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: N/A CAS Number: 1309086-46-1 Current Sponsor code: NNC129-1003 Concentration unit: U unit(s) Concentration type: equal Concentration number: 500-
|
Primary Outcome(s)
|
Primary end point(s): Incidence of inhibitory antibodies against coagulation factor VIII (FVIII) =0.6 Bethesda units
|
Secondary Objective: - To evaluate safety other than immunogenicity of N8-GP - To evaluate efficacy of N8-GP in prophylaxis and treatment of bleeding episodes - To evaluate pharmacokinetic properties of N8-GP and compare to previous FVIII product
|
Main Objective: To evaluate immunogenicity of NNC 0129-0000-1003 (hereafter referred to as N8-GP)
|
Timepoint(s) of evaluation of this end point: During the main phase of the trial (from 0-26 weeks of treatment)
|
Secondary Outcome(s)
|
Timepoint(s) of evaluation of this end point: The pharmacokinetic endpoints on previous FVIII product will be based on assessments performed 2-6 weeks prior to initial dosing with N8-GP and up to 30 hours after administration of previous FVIII product.
The pharmacokinetic endpoints on N8-GP will be based on assessments performed from 1 hour prior to and up to 96 hours after initial administration of N8-GP.
All secondary safety and efficacy endpoints will be analysed and reported separately for the main phase (from 0-26 weeks of treatment) and the extension phase of the trial (from 26 weeks to the last patient has completed the trial).
|
Secondary end point(s): 1. Frequency of adverse events including serious adverse events reported during the trial period
2. Haemostatic effect of N8-GP when used for treatment of bleeding episodes and assessed as: Excellent, Good, Moderate, or None
3. Number of bleeding episodes during prophylactic treatment with N8-GP (annualised bleeding rate)
4. Consumption of N8-GP per bleeding episode (number of injections and U/kg)
5. Consumption of N8-GP during prophylaxis (number of injections and U/kg per month and year)
6. Incremental recovery (defined as the peak level recorded 60 min after end of injection) evaluated for previous FVIII product and N8-GP
7. Area under the curve evaluated for previous FVIII product and N8-GP
8. Terminal half-life evaluated for previous FVIII product and N8-GP
9. Clearance evaluated for previous FVIII product and N8-GP
|
Secondary ID(s)
|
NN7088-3885
|
Source(s) of Monetary Support
|
Novo Nordisk A/S
|
Results
|
Results available:
|
|
Date Posted:
|
|
Date Completed:
|
|
URL:
|
|
|
|